Skip to main content

CORRECTION article

Front. Cardiovasc. Med., 13 May 2022
Sec. Cardiovascular Epidemiology and Prevention
This article is part of the Research Topic Women in Cardiovascular Epidemiology and Prevention View all 35 articles

Corrigendum: Multimorbidity and Polypharmacy in Chinese Emergency Department Patients With Atrial Fibrillation and Impacts on Clinical Outcomes

  • Emergency and Intensive Care Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China

A Corrigendum on
Multimorbidity and Polypharmacy in Chinese Emergency Department Patients With Atrial Fibrillation and Impacts on Clinical Outcomes

by Wang, J., Yang, Y.-m., Zhu, J., Zhang, H., and Shao, X.-h. (2022). Front. Cardiovasc. Med. 9:806234. doi: 10.3389/fcvm.2022.806234

There is an error in the Funding statement. The correct order for funding information is: Capital's Funds for Research and Application of Clinical Diagnosis and Treatment Technology (No. Z191100006619121), National Center for Clinical Research in Cardiovascular Diseases (No. NCRC2020015), and Capital's Funds for Health Improvement and Research (No. 2018-2-4031).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: atrial fibrillation, multimorbidity, polypharmacy, vitamin K antagonist, outcomes, survival

Citation: Wang J, Yang Y-m, Zhu J, Zhang H and Shao X-h (2022) Corrigendum: Multimorbidity and Polypharmacy in Chinese Emergency Department Patients With Atrial Fibrillation and Impacts on Clinical Outcomes. Front. Cardiovasc. Med. 9:900118. doi: 10.3389/fcvm.2022.900118

Received: 20 March 2022; Accepted: 20 April 2022;
Published: 13 May 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Wang, Yang, Zhu, Zhang and Shao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Yan-min Yang, yymfuwai@163.com; ymyang2014@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.